Vizora日本語

Carna BiosciencesCarna Biosciences, Inc.4572東証グロース医薬品FY ending Dec 2025, consolidated, J-GAAP

Carna Biosciences FY ending Dec 2023 results

About 56% of Carna Biosciences's sales come from Drug discovery support business, with Drug discovery business making up much of the rest.

It lost about ¥69 for every ¥100 of sales at the operating level.

Revenue changed +17.2% from the prior year.

What changed from last year

FY ending Dec 2022 → FY ending Dec 2023

Revenue
+17.2%¥1.39B → ¥1.63B
Gross profit
+19.4%¥1.22B → ¥1.45B
Operating income
Loss-¥1.27B → -¥1.12B
Net income attributable to owners
Loss-¥1.35B → -¥1.15B
Operating cash flow
Loss-¥708.4M → -¥1.68B
Free cash flow
Loss-¥834.4M → -¥1.69B

Where the money goes

FY ending Dec 2022 → FY ending Dec 2023

Where ¥100 of sales goes

For every ¥100 Carna Biosciences sells, how much goes where, and how much is kept.

FY ending Dec 2023
Cost of sales
¥11
SG&A
¥158
Operating loss
¥69
Net loss
¥71

Annual margin trends

Gross margin89.2%
FY ending Dec 2019: 93.5%93.5%FY ending Dec 2020: 83.0%83.0%FY ending Dec 2021: 93.3%93.3%FY ending Dec 2022: 87.6%87.6%FY ending Dec 2023: 89.2%89.2%FY19FY20FY21FY22FY23
Operating margin-68.7%
FY ending Dec 2019: 30.5%30.5%FY ending Dec 2020: -93.3%-93.3%FY ending Dec 2021: -26.3%-26.3%FY ending Dec 2022: -91.6%-91.6%FY ending Dec 2023: -68.7%-68.7%FY19FY20FY21FY22FY23
Net margin-70.9%
FY ending Dec 2019: 25.8%25.8%FY ending Dec 2020: -98.0%-98.0%FY ending Dec 2021: -26.5%-26.5%FY ending Dec 2022: -97.3%-97.3%FY ending Dec 2023: -70.9%-70.9%FY19FY20FY21FY22FY23

Aligned fiscal years compare the shares of revenue remaining as gross, core, and net profit. Missing years are left unconnected.

Which businesses earn the money

Revenue by business segment, and the profit each one keeps.

FY ending Dec 2023

Profit by segment

※ Segment figures include inter-segment sales and do not sum to the company total

Sources

Show source documents (6)

  • EDINET (FSA Japan)

    有価証券報告書－第23期(2025/01/01－2025/12/31)

    ID S100XSFK2026-03-26Open

  • EDINET (FSA Japan)

    有価証券報告書－第22期(2024/01/01－2024/12/31)

    ID S100VEU52025-03-26Open

  • EDINET (FSA Japan)

    有価証券報告書－第21期(2023/01/01－2023/12/31)

    ID S100T2Q72024-03-27Open

  • EDINET (FSA Japan)

    有価証券報告書－第20期(2022/01/01－2022/12/31)

    ID S100QFB82023-03-27Open

  • EDINET (FSA Japan)

    有価証券報告書－第19期(令和3年1月1日－令和3年12月31日)

    ID S100NPCS2022-03-25Open

  • EDINET (FSA Japan)

    有価証券報告書－第18期(令和2年1月1日－令和2年12月31日)

    ID S100KZV22021-03-26Open

Extracted from XBRL: 42 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Other periods

Analyze this page with AI

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.

Open MarkdownShare on XSave image